AMT Medical Secures $25 Million to Revolutionize Heart Surgery
April 19, 2025, 9:32 am
Location: Netherlands, Gelderland, Ede
Employees: 11-50
Founded date: 2015
Total raised: $25M
In a bold move to reshape the landscape of cardiac surgery, AMT Medical has successfully raised $25 million in a Series B funding round. This clinical-stage medtech company, based in the Netherlands, is on a mission to transform coronary artery bypass grafting (CABG) with its innovative ELANA Heart Bypass System. The funding round was led by Bender Analytical Holding B.V. (BAH), with participation from Invest-NL, the European Innovation Council (EIC), Oost NL, and several angel investors.
AMT Medical is not just another player in the medtech arena. It’s a pioneer, emerging from the neurovascular ELANA technology that has already made waves in the medical field. With a team of 27 dedicated employees and ISO 13485 certification, the company holds over 40 patents for its groundbreaking surgical platform. The ELANA Heart Bypass System is designed to replace traditional open-heart surgery, offering a minimally invasive alternative that promises to change how heart surgeries are performed.
The funds raised will be pivotal for AMT Medical as it embarks on several key initiatives. One of the primary goals is to achieve CE marking, a crucial step for regulatory approval in Europe. Additionally, the company plans to initiate clinical trials in the United States, focusing on both open and robotic surgical settings. This is not just about funding; it’s about paving the way for a new era in cardiac care.
The ELANA Heart Bypass System is a game-changer. It allows surgeons to perform CABG using arterial grafts through small chest incisions, all while keeping the heart beating. This contrasts sharply with traditional methods that require a sternotomy, or chest cracking, which can lead to longer recovery times and increased risks of complications. By eliminating the need for a heart-lung machine, AMT Medical’s system significantly reduces the chances of stroke and other postoperative issues.
The technology behind the ELANA system is equally impressive. It employs a sutureless anastomosis technique, utilizing a proprietary clip and an excimer laser to connect blood vessels without the need for manual suturing. This method not only enhances precision but also speeds up the process, making it more standardized and reproducible. The result? A reduction in complications and a smoother recovery for patients.
Financially, the ELANA system is poised to make a significant impact. In robotic settings, it can achieve over a 50% cost reduction compared to traditional CABG procedures. This is driven by shorter operating room times, reduced hospital stays, and fewer complications. Patients can often return home within days, a stark contrast to the lengthy recoveries associated with conventional surgeries. Surgeons also benefit from faster mastery of the technique, further streamlining the process.
The implications of this funding and technology extend beyond just patient outcomes. AMT Medical is on a trajectory to redefine cardiovascular care. The company’s vision is clear: to make open-heart bypass surgery obsolete. This is not merely an ambition; it’s a commitment to improving lives and reshaping the future of heart surgery.
As AMT Medical gears up for its next steps, the support from investors signals confidence in its mission. The backing from Bender Analytical Holding and other key players underscores the potential of the ELANA Heart Bypass System to disrupt the status quo in cardiac surgery. With the right resources, AMT Medical is well-positioned to lead the charge in this vital area of healthcare.
The road ahead is filled with challenges, but the potential rewards are immense. As the company moves forward with its clinical trials and regulatory approvals, the eyes of the medical community will be watching closely. If successful, AMT Medical could set a new standard for heart surgery, one that prioritizes patient safety, reduces costs, and enhances recovery times.
In conclusion, AMT Medical’s recent funding round is more than just a financial milestone; it’s a beacon of hope for patients and healthcare providers alike. The ELANA Heart Bypass System represents a significant leap forward in cardiac care, promising to make traditional methods a thing of the past. With innovation at its core and a clear vision for the future, AMT Medical is poised to change the way we think about heart surgery. The heart of the matter is simple: better technology leads to better outcomes. And AMT Medical is ready to lead the way.
AMT Medical is not just another player in the medtech arena. It’s a pioneer, emerging from the neurovascular ELANA technology that has already made waves in the medical field. With a team of 27 dedicated employees and ISO 13485 certification, the company holds over 40 patents for its groundbreaking surgical platform. The ELANA Heart Bypass System is designed to replace traditional open-heart surgery, offering a minimally invasive alternative that promises to change how heart surgeries are performed.
The funds raised will be pivotal for AMT Medical as it embarks on several key initiatives. One of the primary goals is to achieve CE marking, a crucial step for regulatory approval in Europe. Additionally, the company plans to initiate clinical trials in the United States, focusing on both open and robotic surgical settings. This is not just about funding; it’s about paving the way for a new era in cardiac care.
The ELANA Heart Bypass System is a game-changer. It allows surgeons to perform CABG using arterial grafts through small chest incisions, all while keeping the heart beating. This contrasts sharply with traditional methods that require a sternotomy, or chest cracking, which can lead to longer recovery times and increased risks of complications. By eliminating the need for a heart-lung machine, AMT Medical’s system significantly reduces the chances of stroke and other postoperative issues.
The technology behind the ELANA system is equally impressive. It employs a sutureless anastomosis technique, utilizing a proprietary clip and an excimer laser to connect blood vessels without the need for manual suturing. This method not only enhances precision but also speeds up the process, making it more standardized and reproducible. The result? A reduction in complications and a smoother recovery for patients.
Financially, the ELANA system is poised to make a significant impact. In robotic settings, it can achieve over a 50% cost reduction compared to traditional CABG procedures. This is driven by shorter operating room times, reduced hospital stays, and fewer complications. Patients can often return home within days, a stark contrast to the lengthy recoveries associated with conventional surgeries. Surgeons also benefit from faster mastery of the technique, further streamlining the process.
The implications of this funding and technology extend beyond just patient outcomes. AMT Medical is on a trajectory to redefine cardiovascular care. The company’s vision is clear: to make open-heart bypass surgery obsolete. This is not merely an ambition; it’s a commitment to improving lives and reshaping the future of heart surgery.
As AMT Medical gears up for its next steps, the support from investors signals confidence in its mission. The backing from Bender Analytical Holding and other key players underscores the potential of the ELANA Heart Bypass System to disrupt the status quo in cardiac surgery. With the right resources, AMT Medical is well-positioned to lead the charge in this vital area of healthcare.
The road ahead is filled with challenges, but the potential rewards are immense. As the company moves forward with its clinical trials and regulatory approvals, the eyes of the medical community will be watching closely. If successful, AMT Medical could set a new standard for heart surgery, one that prioritizes patient safety, reduces costs, and enhances recovery times.
In conclusion, AMT Medical’s recent funding round is more than just a financial milestone; it’s a beacon of hope for patients and healthcare providers alike. The ELANA Heart Bypass System represents a significant leap forward in cardiac care, promising to make traditional methods a thing of the past. With innovation at its core and a clear vision for the future, AMT Medical is poised to change the way we think about heart surgery. The heart of the matter is simple: better technology leads to better outcomes. And AMT Medical is ready to lead the way.